Amit Srivastava

Amit Srivastava

Auto-generated profile, based on publicly available information

Amit Srivastava

Department of Biological and Environmental Science, Nanoscience Centre, University of Jyvaskyla, Jyvaskyla, Finland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Heliyon
Verified
Journal Article
Open access
AKAnuja Kakkar
Anuja Kakkar
GKGarima Kandwal
Garima Kandwal
TNTanmayee Nayak
Tanmayee Nayak
LJLav Kumar Jaiswal
Lav Kumar Jaiswal
ASAmit Srivastava
Amit Srivastava
AGAnkush Gupta
Ankush Gupta
Antimicrobial resistance (AMR) is a major global concern; antibiotics and other regular treatment methods have failed to overcome the increasing number of infectious diseases. Bacteriophages (phages) are viruses that specifically target/kill bacterial hosts without affecting other human microbiome. Phage therapy provides optimism in the current global healthcare scenario with a long history of its applications in humans that has now reached various clinical trials. Phages in clinical trials have specific requirements of being exclusively lytic, free from toxic genes with an enhanced host range that adds an advantage to this requisite. This review explains in detail the various phage engineering methods and their potential applications in therapy. To make phages more efficient, engineering has been attempted using techniques like conventional homologous recombination, Bacteriophage Recombineering of Electroporated DNA (BRED), clustered regularly interspaced short palindromic repeats (CRISPR)-Cas, CRISPY-BRED/Bacteriophage Recombineering with Infectious Particles (BRIP), chemically accelerated viral evolution (CAVE), and phage genome rebooting. Phages are administered in cocktail form in combination with antibiotics, vaccines, and purified proteins, such as endolysins. Thus, phage therapy is proving to be a better alternative for treating life-threatening infections, with more specificity and fewer detrimental consequences.

1 March 2021 in Trends in Microbiology
Verified
Journal Article
Closed access
ASAmit Srivastava
Amit Srivastava
Rajeev VarshneyRajeev Varshney
Rajeev Varshney
Pratyoosh ShuklaPratyoosh Shukla
Pratyoosh Shukla

17 June 2023 in Trends in Microbiology
Verified
Journal Article
Closed access
PBPiyoosh K. Babele
Piyoosh K. Babele
ASAmit Srivastava
Amit Srivastava
JYJamey Young
Jamey Young

1 January 2022 in Trends in Biotechnology
Verified
Journal Article
Closed access
ASAmit Srivastava
Amit Srivastava
Pratyoosh ShuklaPratyoosh Shukla
Pratyoosh Shukla

20 November 2023 in New Phytologist
Verified
Journal Article
Open access
PSPetra Skotnicová
Petra Skotnicová
ASAmit Srivastava
Amit Srivastava
DADivya Aggarwal
Divya Aggarwal
JTJana Talbot
Jana Talbot
IKIva Karlínová
Iva Karlínová
RSRoman Sobotka
Roman Sobotka
Summary: Biogenesis of the photosynthetic apparatus requires complicated molecular machinery, individual components of which are either poorly characterized or unknown. The BtpA protein has been described as a factor required for the stability of photosystem I (PSI) in cyanobacteria; however, how the BtpA stabilized PSI remains unexplained. To clarify the role of BtpA, we constructed and characterized the btpA‐null mutant (ΔbtpA) in the cyanobacterium Synechocystis sp. PCC 6803. The mutant contained only c. 1% of chlorophyll and nearly no thylakoid membranes. However, this strain, growing only in the presence of glucose, was genetically unstable and readily generated suppressor mutations that restore the photoautotrophy. Two suppressor mutations were mapped into the hemA gene encoding glutamyl‐tRNA reductase (GluTR) – the first enzyme of tetrapyrrole biosynthesis. Indeed, the GluTR was not detectable in the ΔbtpA mutant and the suppressor mutations restored biosynthesis of tetrapyrroles and photoautotrophy by increased GluTR expression or by improved GluTR stability/processivity. We further demonstrated that GluTR associates with a large BtpA oligomer and that BtpA is required for the stability of GluTR. Our results show that the BtpA protein is involved in the biogenesis of photosystems at the level of regulation of tetrapyrrole biosynthesis.

22 September 2022 in Critical Reviews in Biotechnology
Verified
Journal Article
Closed access
ASAmit Srivastava
Amit Srivastava
STShobit Thapa
Shobit Thapa
HCHillol Chakdar
Hillol Chakdar
PBPiyoosh Kumar Babele
Piyoosh Kumar Babele
Pratyoosh ShuklaPratyoosh Shukla
Pratyoosh Shukla
Cyanobacteria safeguard their photosynthetic machinery from oxidative damage caused by adverse environmental factors such as high-intensity light. Together with many photoprotective compounds, they contain myxoxanthophylls, a rare group of glycosidic carotenoids containing a high number of conjugated double bonds. These carotenoids have been shown to: have strong photoprotective effects, contribute to the integrity of the thylakoid membrane, and upregulate in cyanobacteria under a variety of stress conditions. However, their metabolic potential has not been fully utilized in the stress biology of cyanobacteria and the pharmaceutical industry due to a lack of mechanistic understanding and their insufficient biosynthesis. This review summarizes current knowledge on: biological function, genetic regulation, biotechnological production, and pharmaceutical potential of myxoxanthophyll, with a focus on strain engineering and parameter optimization strategies for increasing their cellular content. The summarized knowledge can be utilized in cyanobacterial metabolic engineering to improve the stress tolerance of useful strains and enhance the commercial-scale synthesis of myxoxanthophyll for pharmaceutical uses.